Company Announcement no. 6/2013
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 6 March 2013
Warrant Programme - Registration of capital increase and new Articles of Association following warrant exercise
With reference to Company Announcement no. 5/2013 of 6 March 2013, Veloxis Pharmaceuticals A/S announces that as a consequence of warrant exercise a capital increase of nominal 125,000 new shares with a nominal value of DKK 0.10 each has been registered with the Danish Business Authority today.
Following registration of the new shares, the share capital of Veloxis Pharmaceuticals A/S is nominal DKK 166,057,242.60 divided into shares of DKK 0.10 each.
Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.
The new shares are expected to be admitted to trading and official listing on NASDAQ OMX Copenhagen on 6 March 2013 under the same identification code as the company's existing shares (ISIN: DK0060048148).
The amendment of the Articles of Association entailed by the capital increase has today also been registered with the Danish Business Authority. The new Articles of Association for Veloxis Pharmaceuticals A/S are attached to this announcement and are also available on the company’s website: www.veloxis.com.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Mobile: +1 917 647 9107 Mobile: +45 21 227 227
Email: wjp@veloxis.com Email: jst@veloxis.com
For further information, please visit www.veloxis.com.
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis is a specialty pharmaceutical company. The company's lead product candidate is LCP-Tacro for immunosuppression, specifically organ transplantation. Veloxis' unique, patented delivery technology, MeltDose®, can improve absorption and bioavailability at low scale up costs. Veloxis has a lipid lowering product, Fenoglide®, currently on the U.S. market that is commercialized through partner Santarus, Inc. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
